Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer

Table 2 HPV16 E7 Patient profile, clinical and immmunological outcome

Pt	Age	Path	HPV type	Disease extension	#Vac	Off-Study response/reason	PFS (ms)	OS (ms)	Cr-51	ELISPOT	IR
1B	37	ACA	16	Mets	9	PD	10.0	25.2	+	N/A	+
2B	40	SSC	16	Mets	5	PD	6.3	19.9	+	N/A	+
3B	41	SSC	16	Pelvis	4	PD	4.6	8.5	+	+	+
4B	33	SSC	16	Pelvis	2	PD	2.4	13.9	-	NA	-
5B	53	SSC	16	Mets	4	PD	1.6	7.2	-	+	+
6B	37	SSC	16	Pelvis	1	PD	1.5	4.4	ND	ND	ND
7B	48	SSC	16	Mets	4	PD	1.7	6.3	-	-	-
8B	53	SSC	16	Mets	4	PD	3.6	42.6	-	-	-
9B	37	SSC	16	Pelvis	6	PD	5.3	7.4	-	+	+
10B	68	SSC	16	Pelvis	3	PD	2.5	5.5	-	-	-
11B	49	SSC	16	Mets	8	PD	7.7	7.7+	+	+	+
12B	51	SSC	16	Mets	2	PD	1.6	18.4	-	-	-
13B	45	SSC	16	Mets	6	SD/W	7.5+	7.5+	-	+	+
14B	28	SSC	16	Mets	4	PD	3.5	11.5	NA	NA	NA

Abbreviations: Pt Patient, Path Pathology, #Vac number of administered vaccines, IR Immune Response, ND Not done, NA Not available, Cr-51 Chromium-51 release assay, ELISPOT Enzyme-Linked ImmunoSpot, SCC Squamous Cell Carcinoma, ACA Adenocarcinoma, ASCC Adenosquamous Carcinoma, NED No Evidence of Disease. PD Progression of Disease, PPS Poor Performance Status, SD Stable Disease, Mets metastatic disease, PFS Progression Free Survival, OS Overall Survival, ms Months.

ISSN: 1479-5876